Anti-Smad4 antibody
Specifications
| Product Cat#: | AB-06-4119 |
| Product type: | Primary antibody |
| Antigen: | Smad4 |
| Immunogen: | Recombinant protein |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot ( 1:800-1:2000 ); Immunohistochemistry ( 1:80-1:200 ); Immunocytochemistry ( 1:80-1:200 ); Flow Cytometry ( 1:30-1:100 ); Immunofluorescence |
| Reactivity: | Mouse, Rat and Human |
| Clonality (clone number): | Monoclonal ( SP05-05 ) |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer ( pH7.4 ), 1 % BSA, 40 % glycerol, 0.05 % NaN3. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | (Small) Mothers Against Decapentaplegic Antibody |
| Deleted in Pancreatic Carcinoma 4 Antibody | |
| Deleted in Pancreatic Carcinoma Antibody | |
| Deleted in pPancreatic Carcinoma Locus 4 Antibody | |
| Deletion Target in Pancreatic Carcinoma 4 Antibody | |
| DPC 4 Antibody | |
| DPC4 Antibodyy | |
| hSMAD4 Antibody | |
| JIP Antibody | |
| MAD Homolog 4 Antibody | |
| MAD Mothers Against Decapentaplegic Drosophila homolog 4 Antibody | |
| MAD Mothers Against Decapentaplegic Homolog 4 Antibody | |
| MADH 4 Antibody | |
| MADH4 Antibody | |
| Med Antibody | |
| Medea Antibody | |
| Mothers Against Decapentaplegic Homolog 4 Antibody | |
| Mothers Against Decapentaplegic, Drosophila, Homolog of, 4 Antibody | |
| Mothers Against DPP Homolog 4 Antibody | |
| MYHRS Antibody | |
| OTTHUMP00000163548 Antibody | |
| SMA- and MAD-related Protein 4 Antibody | |
| SMAD 4 Antibody | |
| SMAD Family Member 4 Antibody | |
| SMAD Mothers Against DPP Homolog 4 Antibody | |
| SMAD4 Antibody | |
| SMAD4_HUMAN Antibody |
Target information
In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5′-GTCT/AGAC-3′) within BMP response element (BMPRE) of cardiac activating regions (By similarity). Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling (PubMed:25514493). Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for synergistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.
Provider
Erpantech Laboratory